Age and hypertension related changes in genotypes of MTHFR 677C>T, 1298A>C and PON1 -108C>T SNPs in men with coronary artery disease (CAD)

Journal of Physiology and Pharmacology

Volumn 56, Issue SUPPL. 2, 2005, Pages 65-75

  Strauss, E ^a   Gluszek J ^b   Pawlak, A L ^a  

^a INSTITUTE OF HUMAN GENETICS   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Age; CAD; Case control study; Coronary artery disease; Homocysteine; Homocysteine thiolactone; Hypertension; MTHFR; Polymorphism; PON1; Retrospective study

Indexed keywords

ADULT; AGE; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERTENSION; MALE; MTHFR GENE; PON1 GENE; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGING; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HOMOZYGOTE; HUMANS; HYPERTENSION; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 33845584536     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Inbal A, Freimark D, Modan B, et al. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood 1999; 93: 2186-2190.
2. Refsum H, Smith AD, Ueland PM, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004; 50: 3-32.
3. Girelli D, Martinelli N, Pizzolo F, et al. The interaction between MTHFR 677 C - >T genotype and folate status is a determinant of coronary atherosclerosis risk. J Nutr 2003; 133: 1281-1285.
4. Frosst P, Blom H, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995; 10: 111-113.
5. Van Der Put N., Gabreels F., Stevens E., et al. A second mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62: 1044-1051.
6. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression Am J Hum Genet 2001; 68: 1428-1436.
7. Schalinske KL. Interrelationship between diabetes and homocysteine metabolism: Hormonal regulation of cystathionine beta-synthase. Nutr Rev 2003; 61: 136-138.
8. Cesari M, Zanchetta M, Burlina A, et al. Hyperhomocysteinemia is inversely related with left ventricular ejection fraction and predicts cardiovascular mortality in high-risk coronary artery disease hypertensives. Arlerioscler Thromb Vasc Biol 2005; 25: 115-121.
9. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 2000; 275: 3957-3962.
10. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 1999; 13: 2277-2283.
11. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000; 20: 516-521.
12. Strauss E, Waliszewski K, Głuszek J, Pawlak AL. Among the males bearing the MTHFR 677T allele, the normotensive persons have the greater risk of abdominal aortic aneurysm (AAA) as compared to the hypertensive persons. Eur J Human Genet 2004; 12, suppl. 1: 298.
13. Szczeklik A, Sanak M, Jankowski M, et al. Mutation A1298C of methylenetetrahydrofolate reductase: risk for early coronary disease not associated with hyperhomocysteinemia. Am JMed Genet 2001; 101: 36-39.
14. Matsushita S, Muramatsu T, Arai H, Matsui T, Higuchi S. The frequency of the methylenetetrahydrofolate reductase-gene mutation varies with age in the normal population. Am J Hum Genet 1997; 61: 1459-1460.
15. Todesco L, Angst C, Litynski P, Loehrer F, Fowler B, Haefeli WE. Methylenetetrahydrofolate reductase polymorphism, plasma homocysteine and age. Eur J Clin Invest 1999; 29: 1003-1009.
16. Mackness B, Davies GK, Turkie W, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001; 21: 1451-1457.
17. Leviev I, Poirier O, Nicaud V, et al. High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients. Atherosclerosis 2002; 161: 463-467.
18. Bonafe M, Marchegiani F, Cardelli M, et al. Genetic analysis of Paraoxonase (PON1) locus reveals an increased frequency of Arg192 allele in centenarians. Eur J Hum Genet 2002; 10: 292-296.
19. Rea IM, McKeown PP, McMaster D, et al. Paraoxonase polymorphisms PON1 192 and 55 and longevity in Italian centenarians and Irish nonagenarians. A pooled analysis. Exp Gerontol 2004; 39: 629-635.
20. Campo S, Sardo MA, Trimarchi G, et al. Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians. Exp Gerontol 2004; 39: 1089-1094.
21. Stanger O, Herrmann W, Pietrzik K, et al. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases. Z Kardiol 2004; 93: 439-453.
22. Kokame K, Kato H, Miyata T. Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis. GRP78/BiP and novel genes. J Biol Chem 1996; 271: 29659-29665.
23. Werstuck GH, Lentz SR, Dayal S, et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 2001; 107: 1263-1273.
24. Hossain GS, van Thienen JV, Werstuck GH, et al. TDAG51 is induced by homocysteine, promotes detachment-mediated programmed cell death, and contributes to the development of atherosclerosis in hyperhomocysteinemia. J Biol Chem 2003; 278: 30317-30327.
25. Skurk C, Walsh K. Death Receptor Induced Apoptosis: A New Mechanism of Homocysteine-Mediated Endothelial Cell Cytotoxicity Hypertension 2004; 43: 1168-1170.
26. Lee SJ, Kim KM, Namkoong S, et al. Nitric Oxide Inhibition of Homocysteine-induced Human Endothelial Cell Apoptosis by Down-regulation of p53-dependent Noxa Expression through the Formation of S-Nitrosohomocysteine. J Biol Chem 2005; 280: 5781-5788.
27. Stein S., Thomas E. K., Herzog B., et al. NDRG1 Is Necessary for p53-dependent Apoptosis. J Biol Chem 2004; 279: 48930-48940.
28. Stamler J.S., Osborne J.A., Jaraki O., et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308-318.
29. Boger RH, Lentz SR, Bode-Boger SM, Knapp HR, Haynes WG. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) 2001; 100: 161-167.
30. Romerio SC, Linder L, Nyfeler J, et al. Acute hyperhomocysteinemia decreases NO bioavailability in healthy adults. Atherosclerosis 2004; 176: 337-344.